Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 2 of 34 · 1606 articles
Effective nursing-led support during clinical trial participation may improve engagement, adherence, retention, and timely symptom reporting for people with IBD. That could make trials safer, fairer, and more reliable...
The study presents a novel nanomaterial approach that aims to protect both inflamed intestines and kidneys by restoring intestinal barrier function and microbiome balance—mechanisms relevant to IBD-related systemic...
People with IBD and coexisting primary sclerosing cholangitis (PSC) may get faecal calprotectin tests to monitor colon inflammation. If PSC raises FC independently of colitis, FC could mislead decisions about IBD...
NUDT15 variants strongly affect how people metabolize thiopurine drugs used in IBD; knowing variant frequency helps decide whether routine pre-treatment genotyping is useful in Iran and among specific ethnic groups.
The study links changes in gut microbes and microbial functions with disease activity in children with IBD, suggesting the microbiome may play a role in recovery and could be a target to help sustain remission.
Automated, annotation‑efficient lesion segmentation could speed image review and reduce labeling costs for Crohn’s disease imaging research and tool development. If robust, it may help create better AI tools to support...
This model could improve how researchers study IBD inflammation and early colorectal cancer in a human-derived, multicellular system that reproduces neuromuscular function and immune responses. That may speed preclinical...
The study presents a novel probiotic-based delivery system that targets both intestinal inflammation and anxiety/depression through the gut–brain axis, a potentially relevant concept for people with IBD who commonly...
CVID-related enteropathy can resemble celiac disease or IBD, carries high morbidity and mortality, and often does not respond to standard immunoglobulin therapy — patients and clinicians need awareness of its distinct...
The paper identifies a gut microbiome–driven pathway (flagellin → TLR5 → IL-15 → ARA) that might link intestinal microbial changes to systemic inflammation seen in long COVID and other immune-mediated diseases,...
Improving nursing support during IBD trial pathways could help people stay engaged, understand what participation involves, and report problems earlier—potentially making trials safer and more equitable.
An Expression of Concern signals potential problems with a preclinical IBD study’s data or images. Patients and clinicians should be cautious about relying on that specific animal-study finding when considering...
This paper explores whether polygenic risk scores (PRS) predict key long-term outcomes after IBD diagnosis — notably intestinal surgery — which could be relevant for risk stratification research and future clinical tools...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from JCC Plus.
The study identifies a specific bacterial protein (OmpA) on probiotic-derived vesicles that reduced inflammation in a mouse colitis model by inhibiting TLR4/NF-κB signaling and improving barrier function, suggesting a...
AI chatbots are increasingly used for health information. If chatbot answers about IBD nutrition are inaccurate or hard to read, patients could be confused or misinformed. This study assesses those risks for ChatGPT-3.5.
Faster, more accurate chart abstraction could speed IBD research and quality monitoring while reducing reviewer workload and errors, which may help registries and studies that rely on manually curated EHR data.
This study suggests that circulating monocytes in newly diagnosed Crohn’s disease are transcriptionally and epigenetically reprogrammed toward inflammatory behaviour before they reach the gut, which could help explain...
Prebiotics change how gut microbes ferment carbohydrates and produce metabolites that can affect gut health. For people with IBD, a prebiotic that is well fermented by their microbiota, increases beneficial bacteria and...
The work highlights a dietary polysaccharide that reduced inflammation and improved mucosal barrier function in a mouse colitis model through gut-microbiota changes — a mechanism relevant to IBD research and potential...
Noninvasive intestinal ultrasound with superb microvascular imaging (SMI) may help predict the presence and size of endoscopic ulcers in the terminal ileum of people with Crohn’s disease. That could improve noninvasive...
This preclinical study suggests a plant-derived polysaccharide (THP) can repair the gut vascular barrier and reduce inflammation in experimental colitis via the S1P/S1PR2 pathway, pointing to a novel potential target for...
Understanding how different forms of programmed cell death in the gut lining contribute to barrier loss and inflammation could point to new therapeutic targets for IBD. The review also flags natural products and...
Early lab research suggests Aloe vera components may reduce intestinal inflammation and support mucus barrier repair in a zebrafish model, which could guide future IBD research on plant-derived therapies.
People receiving immune checkpoint inhibitors who develop colitis may face different risks of needing stronger immunosuppression depending on the ICI drug class. Understanding which features predict escalation could...
This study suggests commonly used GLP-1 receptor agonists (semaglutide, liraglutide) were associated with higher symptomatic and endoscopic remission in ulcerative colitis compared with matched controls. If validated,...
The article reviews current and emerging IBD treatments and the biological reasons they may work — useful for patients wanting to understand treatment options and future directions. It highlights therapies beyond...
Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...
Parents and clinicians may wonder whether stressful events in early life increase a child’s long-term IBD risk. This large prospective study found no evidence that the measured early maternal or family adverse events...
This study describes a novel nanoparticle "nanomachine" approach aimed at fixing gut microbial and barrier dysfunction in IBD models and, by doing so, reducing secondary kidney injury—an intersection (gut–kidney axis)...
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study proposes new biomarker candidates (C5AR1, KDM2A, HCAR3) and microbiota-derived metabolites that might interact with those targets. If validated, that could guide future diagnostic tests or microbiome-targeted...
Distinguishing IBD from gastrointestinal tuberculosis is challenging in regions where GITB is common; histologic markers like basal plasmacytosis and eosinophilia on mucosal biopsy could help guide diagnosis when...
Researchers are exploring new small molecules that might modulate T cells in IBD. This study found lab evidence of T‑cell inhibition for several compounds but no therapeutic benefit in a mouse colitis model, so these...
People with IBD may care because this study connects a genetic risk region to a molecular mechanism that restrains inflammation in T cells, offering a potential new biological clue about disease causes and future...
LRMDA may be a previously unrecognized protein important for mucus production and intestinal barrier integrity — processes directly relevant to IBD flares, infection risk, and colorectal cancer development. Understanding...
People with CGD commonly have liver involvement and some develop IBD-like intestinal disease; recognizing and monitoring these complications may affect care and outcomes.
If oxalate from common foods can worsen intestinal inflammation, people with IBD may need to consider how diet affects symptoms and disease activity. This research could point to new dietary counseling or therapies in...
People with UC face higher cardiovascular risk; this study links a specific ITGA4 genetic variant (rs1143674 CC) with subclinical atherosclerosis in UC patients over 40, which could help identify higher-risk individuals...
These results highlight a new cellular mechanism (macrophage-driven ECM changes) that may protect enteric neurons during intestinal inflammation — a process linked to symptoms and complications in IBD.
The work links a specific post-transcriptional regulator (AUF1) to barrier dysfunction in UC and demonstrates that AUF1-restored organoids can enhance mucosal repair in mice, suggesting a possible new regenerative...
Cure8 found this source from Evidence-based complementary and alternative medicine : eCAM, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open...
The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...
The study tested whether early maternal or family adverse events increase later IBD risk and—using two large Scandinavian birth cohorts with registry follow-up—found no association. That may reassure families worried...
The study suggests acetate (sodium acetate) can protect intestinal cells and reshape the gut microbiota in preclinical models of ulcerative colitis, pointing to a potential microbiome-linked therapeutic avenue that might...
This study suggests an environmental fungicide can disrupt gut microbes and reduce beneficial microbial tryptophan metabolites, promoting colitis in mice; dietary tryptophan reversed those effects in the model.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
Microbiota-targeting treatments are an active area of IBD research, and biomaterials may help overcome delivery challenges that limit current microbiome therapies. Advances here could improve how well these approaches...
